TNFRSF8 and anaplastic large cell lymphoma: As brentuximab vedotin combined with CHP (BV-CHP) is currently the standard of care for CD30-positive PTCL and anaplastic large-cell lymphoma (ALCL)17, the efficacy of the IPI and PIT within this treatment context warrants further investigation.